| Updated:
Best of the Brokers for 27 August 2014
To appear in Best of the Brokers, email your research to notes@cityam.com
GREENE KING
Numis has upgraded to “buy’ from “add”, with a target price of 975p. While the broker expects growth to be muted in 2015, it still thinks the long-term strategy at Greene King is right, with faster progress with repositioning, and thinks current weakness presents a buying opportunity.
CLINIGEN
N+1 Singer has maintained its “buy” rating, and increased the target price to 488p from 439p. The broker has upgraded its forecasts following the acquisition of Ethyol from Astrozeneca, providing an attractive addition to Clinigen’s profit-driving speciality pharmaceutical division.